161 related articles for article (PubMed ID: 38366070)
1. Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid.
Burton JM; Youn S; Al-Ani A; Costello F
J Neurol; 2024 May; 271(5):2662-2671. PubMed ID: 38366070
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid eosinophils in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.
Kornbluh AB; Campano VM; Har C; Dwivedi P; Suslovic W; Sepeta L; Kahn I
Mult Scler Relat Disord; 2024 May; 85():105526. PubMed ID: 38489945
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders.
Konuskan B; Yildirim M; Gocmen R; Okur TD; Polat I; Kilic H; Saltik S; Ozturk Z; Gucuyener K; Altunbasak S; Celik T; Kose G; Yilmaz A; Komur M; Kayilioglu H; Anlar B
Mult Scler Relat Disord; 2018 Nov; 26():1-7. PubMed ID: 30212767
[TBL] [Abstract][Full Text] [Related]
4. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability.
Kwon YN; Kim B; Kim JS; Mo H; Choi K; Oh SI; Kim JE; Nam TS; Sohn EH; Heo SH; Kim SB; Park KC; Yoon SS; Oh J; Baek SH; Kim BJ; Park KS; Sung JJ; Jung JH; Kim SJ; Park SH; Waters P; Kim SM
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34711644
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients.
Jarius S; Pellkofer H; Siebert N; Korporal-Kuhnke M; Hümmert MW; Ringelstein M; Rommer PS; Ayzenberg I; Ruprecht K; Klotz L; Asgari N; Zrzavy T; Höftberger R; Tobia R; Buttmann M; Fechner K; Schanda K; Weber M; Asseyer S; Haas J; Lechner C; Kleiter I; Aktas O; Trebst C; Rostasy K; Reindl M; Kümpfel T; Paul F; Wildemann B;
J Neuroinflammation; 2020 Sep; 17(1):261. PubMed ID: 32883348
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients.
Jarius S; Lechner C; Wendel EM; Baumann M; Breu M; Schimmel M; Karenfort M; Marina AD; Merkenschlager A; Thiels C; Blaschek A; Salandin M; Leiz S; Leypoldt F; Pschibul A; Hackenberg A; Hahn A; Syrbe S; Strautmanis J; Häusler M; Krieg P; Eisenkölbl A; Stoffels J; Eckenweiler M; Ayzenberg I; Haas J; Höftberger R; Kleiter I; Korporal-Kuhnke M; Ringelstein M; Ruprecht K; Siebert N; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B; Rostásy K;
J Neuroinflammation; 2020 Sep; 17(1):262. PubMed ID: 32883358
[TBL] [Abstract][Full Text] [Related]
7. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults.
de Mol CL; Wong Y; van Pelt ED; Wokke B; Siepman T; Neuteboom RF; Hamann D; Hintzen RQ
Mult Scler; 2020 Jun; 26(7):806-814. PubMed ID: 31094288
[TBL] [Abstract][Full Text] [Related]
8. Clinical and MRI phenotype of children with MOG antibodies.
Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
[TBL] [Abstract][Full Text] [Related]
9. MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation.
Loos J; Pfeuffer S; Pape K; Ruck T; Luessi F; Spreer A; Zipp F; Meuth SG; Bittner S
J Neurol; 2020 Jun; 267(6):1632-1642. PubMed ID: 32055995
[TBL] [Abstract][Full Text] [Related]
10. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
11. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases.
Baumann M; Hennes EM; Schanda K; Karenfort M; Kornek B; Seidl R; Diepold K; Lauffer H; Marquardt I; Strautmanis J; Syrbe S; Vieker S; Höftberger R; Reindl M; Rostásy K
Mult Scler; 2016 Dec; 22(14):1821-1829. PubMed ID: 26869530
[TBL] [Abstract][Full Text] [Related]
12. Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort.
Ketelslegers IA; Van Pelt DE; Bryde S; Neuteboom RF; Catsman-Berrevoets CE; Hamann D; Hintzen RQ
Mult Scler; 2015 Oct; 21(12):1513-20. PubMed ID: 25662345
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis.
Nakajima H; Motomura M; Tanaka K; Fujikawa A; Nakata R; Maeda Y; Shima T; Mukaino A; Yoshimura S; Miyazaki T; Shiraishi H; Kawakami A; Tsujino A
BMJ Open; 2015 Apr; 5(4):e007766. PubMed ID: 25838512
[TBL] [Abstract][Full Text] [Related]
14. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
Jitprapaikulsan J; Chen JJ; Flanagan EP; Tobin WO; Fryer JP; Weinshenker BG; McKeon A; Lennon VA; Leavitt JA; Tillema JM; Lucchinetti C; Keegan BM; Kantarci O; Khanna C; Jenkins SM; Spears GM; Sagan J; Pittock SJ
Ophthalmology; 2018 Oct; 125(10):1628-1637. PubMed ID: 29716788
[TBL] [Abstract][Full Text] [Related]
15. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
[TBL] [Abstract][Full Text] [Related]
16. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes.
Waters P; Fadda G; Woodhall M; O'Mahony J; Brown RA; Castro DA; Longoni G; Irani SR; Sun B; Yeh EA; Marrie RA; Arnold DL; Banwell B; Bar-Or A;
JAMA Neurol; 2020 Jan; 77(1):82-93. PubMed ID: 31545352
[TBL] [Abstract][Full Text] [Related]
17. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
Bruijstens AL; Lechner C; Flet-Berliac L; Deiva K; Neuteboom RF; Hemingway C; Wassmer E; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
Eur J Paediatr Neurol; 2020 Nov; 29():2-13. PubMed ID: 33162302
[TBL] [Abstract][Full Text] [Related]
18. High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics.
Lui A; Chong J; Flanagan E; Abrams AW; Krysko KM; Arikan B; Francisco C; Rutatangwa A; Waubant E; Ziaei A
Mult Scler Relat Disord; 2021 Nov; 56():103253. PubMed ID: 34517190
[TBL] [Abstract][Full Text] [Related]
19. MOG antibody-associated encephalomyelitis/encephalitis.
Salama S; Khan M; Pardo S; Izbudak I; Levy M
Mult Scler; 2019 Oct; 25(11):1427-1433. PubMed ID: 30907249
[TBL] [Abstract][Full Text] [Related]
20. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases.
Mariotto S; Gajofatto A; Batzu L; Delogu R; Sechi G; Leoni S; Pirastru MI; Bonetti B; Zanoni M; Alberti D; Schanda K; Monaco S; Reindl M; Ferrari S
Neurology; 2019 Nov; 93(20):e1867-e1872. PubMed ID: 31645473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]